
Boston venture fund making early-stage investments in founders chosen for emotional intelligence

Life sciences venture firm backing drug development companies with a scientific advisory board and venture advisers

Pappas Capital is a venture investment firm with a focus on pharmaceutical and biotechnology companies. Its team includes a scientific advisory board and a group of venture advisers with backgrounds in drug development.
The firm supports the companies it backs with clinical development guidance from experienced industry figures.
Drug developers in its portfolio, including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals. Lumena was later acquired by Shire in 2014.
Profile written by TrustList from the business's own published information, Oct 2026.
2 images — click to enlarge
As of 2026-10-05. Organic ranks only; sponsored placements are never ranks.
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Pappas Capital.
Similar listings buyers compare against this one.

Boston venture fund making early-stage investments in founders chosen for emotional intelligence

Los Angeles venture fund investing in early-stage companies across finance, health, consumer and entertainment

UK EIS and SEIS funds investing in early-stage biotech therapeutics and related AI

Family of global venture capital funds investing in artificial intelligence and machine learning companies

Venture capital fund-of-funds investor that backs venture managers and start-ups

Nabais Capital
Everything here links back to the same verified catalogue. Pick your next stop.